Artwork

Matthew Weiner, MD and Zoe Schroeder, RD, Matthew Weiner, MD, Zoe Schroeder, and RD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Matthew Weiner, MD and Zoe Schroeder, RD, Matthew Weiner, MD, Zoe Schroeder, and RD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

10 Predictions for 2024

34:42
 
공유
 

Manage episode 393288201 series 3531512
Matthew Weiner, MD and Zoe Schroeder, RD, Matthew Weiner, MD, Zoe Schroeder, and RD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Matthew Weiner, MD and Zoe Schroeder, RD, Matthew Weiner, MD, Zoe Schroeder, and RD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Could Zepbound, the latest GLP-1 medication, eclipse the success of weight loss giant Wegovy? Tune in as we dissect the burgeoning revolution in obesity treatment, where medications such as Ozempic and Mounjaro are redefining the approach to this stubborn metabolic disease. We unpack the stunning efficacy of Zepbound, debate its potential to rival bariatric surgery outcomes, and confront the crucial issue of medication accessibility. Drawing on expert insights, we offer predictions on how Zepbound might reshape the availability and affordability of weight loss treatments in the upcoming year, navigating the complexities of supply chain disturbances and pharmaceutical management.
The conversation takes a futuristic turn with the introduction of AI into the weight management arena. Imagine a world where meal planning and health resources are fine-tuned by intelligent algorithms, shaping the way consumers and healthcare providers tackle obesity. We scrutinize Novo Nordisk's supply dilemmas but offer kudos to Eli Lilly for their adept handling of Mounjaro distribution. The narrative then shifts to the adventurous—patients sourcing GLP-1 drugs from overseas to bypass insurance hurdles and the growing trend of non-diabetics using continuous glucose monitoring. We peel back the layers of these trends to reveal their implications for the future of weight loss and health management.
Lastly, we ponder the changing landscape of bariatric surgery amid the rise of GLP-1 medications, discussing the decline in surgery rates and the exciting potential for combination therapies. We also stir the pot on lifestyle shifts, spotlighting the conscious reduction in caffeine and alcohol intake for improved sleep and overall wellness. Our commitment to bringing you the latest insights in health and fitness remains unwavering. With our finger on the pulse, we promise another year of thought-provoking discussions and invaluable content that will keep you informed and motivated on your health journey.

  continue reading

챕터

1. Weight Loss Trends for 2024 (00:00:00)

2. Zepbound IN, Ozempic OUT (00:01:05)

3. Keto OUT, Plant-Based IN (00:05:03)

4. Harder to get GLP-1's through Insurance (00:07:45)

5. AI Uses for Weight Loss Increase (00:12:12)

6. Lots of People will get Mounjaro from Canada (00:16:36)

7. Non-Diabetic Glucose Monitoring Becomes More Popular (00:19:10)

8. Compounded GLP-1 Meds are OUT (00:22:20)

9. Less HIIT, More Strength Training (00:24:34)

10. Bariatric Surgery + GLP-1 medications will become the Gold Standard (00:27:55)

11. People will Start Eliminating Caffeine (00:30:18)

27 에피소드

Artwork
icon공유
 
Manage episode 393288201 series 3531512
Matthew Weiner, MD and Zoe Schroeder, RD, Matthew Weiner, MD, Zoe Schroeder, and RD에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Matthew Weiner, MD and Zoe Schroeder, RD, Matthew Weiner, MD, Zoe Schroeder, and RD 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Could Zepbound, the latest GLP-1 medication, eclipse the success of weight loss giant Wegovy? Tune in as we dissect the burgeoning revolution in obesity treatment, where medications such as Ozempic and Mounjaro are redefining the approach to this stubborn metabolic disease. We unpack the stunning efficacy of Zepbound, debate its potential to rival bariatric surgery outcomes, and confront the crucial issue of medication accessibility. Drawing on expert insights, we offer predictions on how Zepbound might reshape the availability and affordability of weight loss treatments in the upcoming year, navigating the complexities of supply chain disturbances and pharmaceutical management.
The conversation takes a futuristic turn with the introduction of AI into the weight management arena. Imagine a world where meal planning and health resources are fine-tuned by intelligent algorithms, shaping the way consumers and healthcare providers tackle obesity. We scrutinize Novo Nordisk's supply dilemmas but offer kudos to Eli Lilly for their adept handling of Mounjaro distribution. The narrative then shifts to the adventurous—patients sourcing GLP-1 drugs from overseas to bypass insurance hurdles and the growing trend of non-diabetics using continuous glucose monitoring. We peel back the layers of these trends to reveal their implications for the future of weight loss and health management.
Lastly, we ponder the changing landscape of bariatric surgery amid the rise of GLP-1 medications, discussing the decline in surgery rates and the exciting potential for combination therapies. We also stir the pot on lifestyle shifts, spotlighting the conscious reduction in caffeine and alcohol intake for improved sleep and overall wellness. Our commitment to bringing you the latest insights in health and fitness remains unwavering. With our finger on the pulse, we promise another year of thought-provoking discussions and invaluable content that will keep you informed and motivated on your health journey.

  continue reading

챕터

1. Weight Loss Trends for 2024 (00:00:00)

2. Zepbound IN, Ozempic OUT (00:01:05)

3. Keto OUT, Plant-Based IN (00:05:03)

4. Harder to get GLP-1's through Insurance (00:07:45)

5. AI Uses for Weight Loss Increase (00:12:12)

6. Lots of People will get Mounjaro from Canada (00:16:36)

7. Non-Diabetic Glucose Monitoring Becomes More Popular (00:19:10)

8. Compounded GLP-1 Meds are OUT (00:22:20)

9. Less HIIT, More Strength Training (00:24:34)

10. Bariatric Surgery + GLP-1 medications will become the Gold Standard (00:27:55)

11. People will Start Eliminating Caffeine (00:30:18)

27 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드